MDT · Medtronic
Conviction · Medium · more likely to lead the S&P 500 over the next three months, by a modest margin
Wrong if: a daily close below $93
Note written ·
Price against the kill line
10.0% clear of its kill line on the 17 November 2026 close.
How to read this
The red mark is the price level of the published kill line: a close through it (a weekly close, on a weekly line) would prove the research note wrong on price. The dot is where the stock closed on 17 November 2026; a dot left of the mark has closed through its line.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close below $93.00, set on 14 November 2026. The shares are up 9.4% since the close; the S&P 500 is down 4.5% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close below $93, under the 50-day moving average as of 13 November 2026, which would show the autumn rally failing; or a lowered fiscal 2027 organic revenue growth outlook at the 24 November 2026 report.
Research onlyNot in the portfolio.
Catalyst
The business · as of
Medtronic makes medical devices and sells them mainly to hospitals and health systems. Its lines include pacemakers, heart-ablation systems, spine and brain-stimulation devices, and surgical tools, and it earns money mostly on device and disposable sales. Revenue was $9,756 million in the quarter to 31 July 2026 (10-Q filed 3 September 2026).
What is changing, and what follows · as of
- What is changing now
- On 1 September 2026 Medtronic raised its fiscal 2027 organic growth guidance to 7.25–7.75% as Cardiac Ablation Solutions grew 88%. On 14 October 2026 it swapped its entire MiniMed stake for 55,032,401 of its own shares.
- What follows for the company
- Without Diabetes, revenue and earnings rest more on cardiovascular devices, and fewer shares carry those earnings. Free cash flow was $6,132 million over four quarters, against $28,153 million of debt at 31 July 2026.
- What follows for its customers, suppliers and competitors
- Faster ablation growth takes share from Boston Sciential-type rivals Boston Scientific (BSX), Johnson & Johnson (JNJ) and Abbott (ABT). OrthoPediatrics (KIDS) launched a spine system using Medtronic-licensed technology on 9 November 2026.
What the price assumes · as of
At the 13 November 2026 close (filed inputs to 3 September 2026), the shares trade at P/E 25.2, EV/sales 4.0 and EV/EBIT 22.2, with a free-cash-flow yield of 4.7%, on an enterprise value of $150,906 million. Those multiples hold only if organic growth stays near the raised 7.25–7.75% fiscal 2027 outlook and the operating margin climbs above the 18.1% of the latest filed quarter.
Key figures from the filings · Health Care
Quarter to 31 July 2026, filed 3 September 2026; valuation at the 17 November 2026 close
- Revenue, latest quarter ($M)
- 9,756
- Revenue, change on a year (%)
- +13.7
- Gross margin (%)
- 65.0
- Operating margin (%)
- 18.1
- Free cash flow, four quarters ($M)
- 6,132
- Net cash, cash less debt ($M)
- −19,334
- Price to earnings (×)
- 25.0
- Enterprise value to sales (×)
- 4.0
All filed numbers
What Medtronic reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 9,756 | +13.7 | 65.0 | 18.1 |
| first filed | 9,807 | +9.9 | 65.4 | 19.1 |
| first filed | 9,017 | +8.7 | 63.8 | 16.2 |
| first filed | 8,961 | +6.6 | 65.8 | 18.8 |
| first filed | 8,578 | +8.4 | 65.0 | 16.8 |
| first filed | 8,927 | +3.9 | 64.7 | 16.1 |
| Pre-tax income ($M) | 1,769 |
| Net income ($M) four quarters: 5,231 | 1,470 |
| Diluted shares, change on a year (%) against the quarter to 25 July 2025 | −0.2 |
| Operating cash flow ($M) | 8,035 |
| Capital spending ($M) | 1,903 |
| Free cash flow ($M) | 6,132 |
| Cash and short-term investments ($M) | 8,819 |
| Debt ($M) non-current long-term debt and finance leases plus current debt | 28,153 |
| Net cash, cash less debt ($M) | −19,334 |
| Deferred revenue ($M) +13.1% on a year | 500 |
| Backlog, orders not yet delivered ($M) 0.0% on a year | 400 |
| Receivables ($M) | 6,357 |
| Inventory ($M) | 6,215 |
| Shareholders' equity ($M) | 50,232 |
| Market value ($M) | 130,881 |
| Enterprise value, market value plus net debt ($M) | 150,215 |
| Enterprise value to sales (×) | 4.0 |
| Enterprise value to operating income (×) | 22.1 |
| Price to earnings (×) | 25.0 |
| Price to book value (×) | 2.6 |
| Free-cash-flow yield (%) | 4.7 |
Short interest (FINRA, settled 30 October 2026, published 10 November 2026): 1.8% of shares outstanding sold short, 1.9 days of average trading to cover, −83.5% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 days | Not available yet | Not available yet |
| 12 months | Not available yet | Not available yet |
Linked companies · as of
- Customers:
- KIDS
The thesis
Medtronic is modestly more likely than not to beat the S&P 500 over the next three months. Its heart-rhythm business is growing fastest, and the October split-off of MiniMed cut the share count. The fiscal second-quarter report on 24 November 2026 shows whether growth holds once the extra week that lifted the first quarter is gone.
First-quarter revenue for the period to 31 July 2026 was $9,756 million, up 13.7% from a year earlier. The 1 September 2026 results release said Cardiac Ablation Solutions grew 88% organically. Management raised fiscal 2027 organic revenue growth guidance to 7.25–7.75% and non-GAAP earnings per share guidance to $5.94–6.00. The company estimated that a 53rd fiscal week added about $570 million to the quarter, so underlying growth was lower than the headline figure.
The MiniMed exchange offer closed on 14 October 2026. Medtronic accepted 55,032,401 of its own shares in exchange for all 252,813,348 MiniMed shares it held, according to the company's final-results release. Holders tendered 297,521,390 shares, about 5.4 times the number accepted. The rating is Medium. The growth evidence is dated and filed, but at 25.2 times earnings the price already pays for much of it.
Bullish and bearish views on Medtronic plc
The bull case on Medtronic plc (MDT), in brief: pulsed-field ablation is driving growth. The bear case: the extra week flattered the first quarter.
Bull case
- Pulsed-field ablation is driving growth. Cardiac Ablation Solutions grew 88% organically and Electrophysiology Therapies 29.1% in the quarter to 31 July 2026, lifting Cardiovascular to 18.9% organic growth (results release, 1 September 2026).
- Guidance went up after a beat. On 1 September 2026 Medtronic raised fiscal 2027 organic growth guidance from 6.75–7.25% to 7.25–7.75%, after first-quarter revenue came in about 200 basis points above the midpoint of its own guidance.
- Split-off retired shares at a discount. On 14 October 2026 Medtronic retired 55,032,401 of its shares in exchange for the MiniMed stake, at the capped ratio of 4.5939 MiniMed shares per Medtronic share set on 7 October 2026.
- New clinical and label data in hypertension. On 3 November 2026 Medtronic reported six-month blood pressure reductions in the SPYRAL AFFIRM study, and the FDA approved a label update that includes the data. Real-world renal denervation evidence with Recor Medical followed on 6 November 2026.
- Cash generation covers the dividend and the debt. Free cash flow was $6,132 million over the four quarters to 31 July 2026, against $28,153 million of debt at that date (10-Q filed 3 September 2026).
- Analyst targets moved up after the results. Bank of America Securities raised its target from $110 to $120 on 9 November 2026 and kept a bullish rating.
Bear case
- The extra week flattered the first quarter. The company put the 53rd-week contribution at about $570 million of the $9,756 million first-quarter revenue (1 September 2026). The second-quarter comparison does not get that help.
- Margins have not widened. The operating margin was 18.1% in the quarter to 31 July 2026, below the 18.8% of the quarter to 24 October 2025 and the 19.1% of the quarter to 24 April 2026 (10-Q filings).
- Executives sold into the rally. Chairman and CEO Geoffrey Martha sold 50,000 shares at $95.00 and Michael Marinaro sold 10,420 shares at $96.00 on 15 October 2026, both under Rule 10b5-1 plans (SEC Form 4 filings, 16 October 2026).
- The Diabetes business is gone, and its growth with it. Diabetes posted $843 million of revenue and 14.9% organic growth in the quarter to 31 July 2026 (results release, 1 September 2026). After the 14 October 2026 exchange it is no longer part of Medtronic.
- Leverage is material. Net debt was $19,334 million at 31 July 2026, with cash and short-term investments of $8,819 million against $28,153 million of debt (10-Q filed 3 September 2026).
Price setup
The shares closed at $102.86 on 13 November 2026. That is 3.3% below the 52-week intraday high of $106.33 set on 26 November 2025, and well above the 52-week closing low of $73.75 on 2 June 2026. The 3-month change is 14.2%, from an adjusted $90.05 on 17 August 2026.
As of 13 November 2026, the 50-day moving average stood at $93.57 and the 200-day at $87.39, both below the last close. Between 6 November 2026 and 13 November 2026 the shares closed between $100.99 and $102.86. The prior high near $106 is the level the shares would need to clear to show investors paying more than they did a year ago.
The quarterly report is the next large price event. What matters is what the report shows about growth without the extra week and the new outlook without Diabetes.
Catalysts ahead
- 24 November 2026: Fiscal second-quarter 2027 results. This is the first quarter without the extra-week lift and the first report since the MiniMed separation. It shows whether ablation-led growth holds and whether the fiscal 2027 outlook stands once Diabetes is removed.
What would change the view
A daily close below $93, under the 50-day moving average as of 13 November 2026, which would show the autumn rally failing; or a lowered fiscal 2027 organic revenue growth outlook at the 24 November 2026 report.
The risks this note tracks, each with what would confirm it:
- Growth slows sharply once the 53rd-week lift is gone. Confirmed by: second-quarter organic revenue growth reported on 24 November 2026 falls back toward the 6.6% of the quarter to 24 October 2025.
- Competition in pulsed-field ablation slows Medtronic's share gains. Confirmed by: Cardiac Ablation Solutions growth slows steeply from the 88% of the quarter to 31 July 2026, while Boston Scientific (BSX) reports faster ablation growth.
- Losing MiniMed's earnings outweighs the benefit of the retired shares. Confirmed by: fiscal 2027 non-GAAP earnings per share guidance recast below the $5.94 low end at the 24 November 2026 report.
- Operating margin stalls while the price assumes it widens. Confirmed by: operating margin in the quarter to late October 2026 falls below the 18.1% of the quarter to 31 July 2026.
What it trades with
Medtronic trades with large-cap medical-device makers, mainly Boston Scientific (BSX) and Abbott (ABT), its closest rivals in heart rhythm and ablation. Results from those companies on pulsed-field ablation demand move Medtronic's shares, and the reverse also holds. With MiniMed separated, the shares no longer carry direct exposure to insulin pumps and diabetes technology, which links them less to Dexcom (DXCM) and Insulet (PODD).
The evidence, claim by claim (8)
- Revenue for the first quarter of fiscal 2027 was $9,756 million, up 13.7% as reported and organically. The company estimated that an extra fiscal week added about $570 million. Medtronic first-quarter fiscal 2027 results release · as of
- Cardiac Ablation Solutions grew 88% organically, Electrophysiology Therapies 29.1% and the Cardiovascular segment 18.9% in the quarter to 31 July 2026. Medtronic first-quarter fiscal 2027 results release · as of
- Fiscal 2027 guidance was raised to 7.25–7.75% organic revenue growth and $5.94–6.00 non-GAAP diluted earnings per share. Medtronic first-quarter fiscal 2027 results release · as of
- Medtronic accepted 55,032,401 of its ordinary shares in exchange for 252,813,348 MiniMed shares, its entire remaining stake. Holders tendered 297,521,390 shares. Medtronic final results of MiniMed exchange offer release · as of
- Chairman and CEO Geoffrey Martha sold 50,000 shares at $95.00 under a Rule 10b5-1 plan. SEC Form 4 filed 16 October 2026 · as of
- Free cash flow was $6,132 million over the four quarters to 31 July 2026, and debt was $28,153 million at that date. Medtronic 10-Q filed 3 September 2026 · as of
- Medtronic reported six-month blood pressure reductions in the SPYRAL AFFIRM study and received FDA approval for a label update that includes the data. Medtronic company news · as of
- Bank of America Securities raised its Medtronic price target from $110 to $120 and kept a bullish rating. Bank of America Securities analyst Travis Steed · as of
Sources
Related · shared themes
ADPT
Adaptive Biotechnologies
Adaptive Biotechnologies is more likely than not to beat the S&P 500 over three months because clonoSEQ tests rose 46% in the third quarter…
AXGN
Axogen
Axogen's nerve-repair revenue grew 26.2% last quarter and a $754 million prostate market sits outside guidance, giving the shares a modest…
CSTL
Castle Biosciences
Castle Biosciences is modestly more likely than not to beat the S&P 500 over three months, because its TissueCypher test drove 24% revenue…
DXCM
DexCom
Dexcom's raised 2026 outlook and 25.3% third-quarter operating margin give the shares a modest edge after a diabetes-device sell-off erased…